60+ Presentations from Top Biopharma in 2023
Optimisation of Antibody Developability Properties Using Deep-Learning Predictive Models
James R. Apgar, PhD, Associate Research Fellow, BioMedicine Design, Pfizer Inc.
Developability Strategy for Large Molecule Therapeutics: Integrating in silico and Wet Lab Approaches
Maniraj Bhagawati, PhD, Lab Head, Functional Characterization, Large Molecule Research, Roche pRED
Bispecific Antibodies: Preclinical and Translational Strategies to Support Clinical Dose Setting
Esther C.W. Breij, PhD, Vice President, Head of Translational Research, Genmab BV
Antibody Chain-Exchange Based Approaches to Generate and Optimize Bispecific Antibodies, Prodrugs, and ADCs
Ulrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center
ML and Computational Tools for Biologic Molecule Design and Insight
Andrew Buchanan, PhD, FRSC, Principal Scientist, Biologics Engineering, Oncology, AstraZeneca
ImmTAC: A High-Affinity Soluble TCR Bispecific Platform to Target Cancers
Chandramouli Chillakuri, PhD, Associate Director, Protein Engineering, Immunocore Ltd.
PD-1-cis IL-2R Agonism Yields Better Effectors from Stem-Like CD8+ T cells
Laura Codarri Deak, PhD, Senior Principal Scientist, Cancer Immunotherapy, Roche Innovation Center
Benchmarking the Impact of AI Biologics Discovery and Optimisation for Pharma
Rebecca Croasdale-Wood, PhD, Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca
HexElect: Logic-Gated Antibody Pairs that Selectively Act on Cells Co-Expressing Two Antigens
Rob N. de Jong, PhD, Senior Director and Head, Antibody Format Development, Genmab BV
A Patient-First Approach to Discover First-in-Class Antibody Therapeutics
Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics Ltd.
Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies
David J. DiLillo, PhD, Senior Director, Regeneron Pharmaceuticals, Inc.
Mammalian Antibody Display: Microfluidic Hit Discovery and Their Fruitful Combination
Achim Doerner, PhD, Principal Scientist, Protein Engineering & Antibody Technologies, Merck Healthcare KGaA
Computational Counterselection Identifies Nonspecific Therapeutic Biologic Candidates
Stefan Ewert, PhD, Associate Director, Biologics Center, Novartis Institutes for Biomedical Research
Bispecific and Next-Generation Antibodies for Non-Oncology Indications such as Ophthalmologic and Neurologic Diseases
Jens A. Fischer, PhD, Program Manager, Large Molecule Research Therapeutic Modalities, Roche Pharma Research and Early Development (pRED)
Lab in the Loop, an ML-Driven Platform for Automated Molecular Discovery and Design
Nathan Frey, PhD, Machine Learning Scientist, Prescient Design, a Genentech Company
Towards Biologics by Design: Computational & AI-Based Optimization of Multi-Specific Protein Therapeutics
Norbert Furtmann, PhD, Head, Computational & High-Throughput Protein Engineering, Large Molecule Research, Sanofi
MS-Based Cell Bioassays: A Novel Tool for Biotherapeutics Characterization
Christian Graf, PhD, Fellow, Scientific Office, Novartis
Using Machine Learning to Predict Protein Expression
Lovisa Holmberg Schiavone, PhD, Director, Discovery Biology, Discovery Sciences, R&D, AstraZeneca
Improving Safety and Dose Accuracy of IV Administration for Protein Drug Products
Qingyan Hu, PhD, Associate Director, Protein Formulation Development, Regeneron Pharmaceuticals, Inc.
The New Age of Immunotherapy: From Checkpoint Inhibitors to Vaccines
Nageatte Ibrahim, MD, Vice President, Oncology & Global Clinical Development, MSD
Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA
Developing Internal AI Capabilities via External Collaborations and Internal Resources
Hubert Kettenberger, PhD, Head, Computational Protein Engineering, Roche
Understanding and Overcoming Surfactant-Related Stability Challenges
Tarik A. Khan, PhD, Senior Principal Scientist, PTD Biologics, F. Hoffmann-La Roche AG
Discovery of Antibody-Based Therapeutics to Challenging Targets: Platform Considerations
Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen
Science and Risk-Based Shelf-Life Prediction for Protein Biologics
Andrew A Kosky, PhD, Sr Director, Technical Development, Genentech Inc.
Reprogramming CAR T Cells in vivo Using Targeted LNPs
Viktor Lemgart, PhD, Research Fellow, Tidal Therapeutics, a Sanofi Company
Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics
Giuseppe L. Licari, PhD, Lead Scientist, Computational Structural Biology, Global Drug Product Development - BDC, Merck Serono SA
Molecule Formats for Tumor Targeting of Radiotherapies
Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare AG
Automation and Closed Loop Optimization of Protein Development Processes
James D. Love, PhD, Vice President, Automation & Process Optimization, Novo Nordisk AS
Higher-Order Structure, Behavior, and Interactions of Novel Biotherapeutics
Mark McCoy, PhD, Principal Scientist, Quantitative Biosciences, Merck & Co.
Discovery and Characterization of Highly Potent Fc-enhanced Anti-GPCR mAbs
Laura Mele, PhD, Investigator, GlaxoSmithKline
Learning Antibody Binding Affinity Using FACS and NGS
Iain H. Moal, PhD, Scientific Leader, Computational Antibody Engineering, GlaxoSmithKline
A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker is Processed in Recycling and Late Endosomes
Andres Perez Bay, PhD, Senior Staff Scientist, Oncology & Angiogenesis, Regeneron Pharmaceuticals, Inc.
T Cell Redirecting Antibodies for the Treatment of Hematological Malignancies
Ulrike Philippar, PhD, Senior Director & Head, Oncology & Discovery Hematological Malignancies, Janssen Pharmaceutica NV
Low-Data Interpretable Deep Learning Prediction of Antibody Viscosity Using a Biophysically Meaningful Representation
Brajesh K. Rai, PhD, Senior Director, Machine Learning Computational Sciences, Pfizer Inc.
Cryo-EM Structure and Epitope/Paratope Mapping of CEACAM5 Monoclonal Antibody Targeting
Alexey Rak, PhD, Head, Biostructure and Biophysics, Sanofi
Rapid Purification of Multi-Specific Antibodies Enabled by Introduction of Engineered Mutations
David J. Reczek, PhD, Head of US Operations, Large Molecule Research, Sanofi
An Automated DNA Assembly Framework Enables Rapid and Scalable Plasmid Generation for Drug Discovery Applications
Robert G. Roth, PhD, Director, Protein Expression & Molecular Biology, Discovery Biology, R&D Biopharmaceuticals, AstraZeneca
scifAI: An Explainable Machine Learning Framework Applied to Functional Characterization of Therapeutic Antibodies
Fabian Schmich, PhD, Senior Data Scientist, pRED Informatics, Roche Diagnostics Deutschland GmbH
Stabilized GPCRs for Antibody Discovery
Jendrik Schöppe, PhD, Senior Scientist, Novo Nordisk
Interlaboratory Study of Multi-Attribute Method by Peptide Mapping Liquid Chromatography Mass Spectrometry (MAM) Performance across Novartis Analytical Development Sites
Maja Semanjski Curkovic, PhD, Science & Technology Expert, Process Analytical Sciences Tech R&D, Novartis Pharmaceuticals
Challenges of Working with a Two-Faced Bispecific — One Size Does Not Fit All
Laura Sewell, Scientist, Biopharmaceutical Development, AstraZeneca
Enhancing Antibody Discovery with Generative AI
Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi
Interactions between Preservatives and an IgG1 mAb in Support of Multi-Dose Formulation Development for Biologics
Ramesh Kumar Shanmugam, PhD, MBA, Associate Director, Biopharmaceutical Development, AstraZeneca
Case Studies on the Application of New Tools and Approaches for Current Challenges in Formulation Development of Antibody-Based Drugs
Michael Siedler, PhD, Section Head, NBE Formulation Sciences & Process Development, Abbvie Deutschland GmbH & Co. KG
Tumor-Targeted Costimulation via CD28 Bispecific Antibodies: Turning Immunotherapy “Cold” Tumors “Hot"
Dimitris Skokos, PhD, Senior Director, Cancer Immunology, Regeneron Pharmaceuticals
Approaches to High-Throughput Expression and Machine Learning at GSK
Kate J. Smith, PhD, Director, UK Protein & Cell Sciences, GlaxoSmithKline
Tumor-Targeted CD28 Bispecific Antibodies Preferentially Enhance T Cell Costimulation and Activation in the Tumor Microenvironment
David E. Szymkowski, PhD, Vice President Preclinical Operations, Xencor, Inc.
Enhancing Success Rates and Throughput of Protein Purification for Drug Discovery: A Medium-Scale Approach
Sandeep K. Talapatra, PhD, Leader Protein Science, Protein Cell & Structural Sciences, GlaxoSmithKline
GPCR Production Strategies to Enable Antibody Discovery and Characterization
Keenan Taylor, PhD, Senior Scientist, AbbVie, Inc.
Graph-pMHC: Graph Neural Network Approach to MHC Class II Peptide Presentation and Antibody Immunogenicity
Will Thrift, PhD, Senior Artificial Intelligence Scientist, Genentech
Approaches to Immunogenicity Risk Assessment of mRNA-LNP Products
Sophie Tourdot, PhD, Immunogenicity Sciences Lead, BioMedicine Design, Pfizer Inc.
Characterization of Full/Empty AAV Capsids
Dana Tribby, Associate Scientist III, Analytical Development & Gene Therapy Chemistry, Biogen
A Novel Tumor-Selective Anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor Microenvironment
Ryo Uchikawa, Pharmacologist, Chugai Pharmaceutical Co., Ltd.
Structure-Guided Tuning of T Cell Receptors for HLA-A*03:01/A*11:01 Alloselectivity
Annelise Vuidepot, PhD, Senior Vice President and CTO, Immunocore
Non-mAb Biotherapeutics: A Paradigm Change for the Developability Assessment Concept?
Paul Wassmann, PhD, Senior Principal Scientist, NIBR Biologics Center, Novartis
Next Generation Biologics Engineering Platform: From Conventional Screening to Early Multiparameter Deep Characterization and Machine Learning-Based Properties Prediction
Ernst Weber, PhD, Head, Molecular Design & Engineering, Bayer AG
Launching into the Future: Sanofi’s Biologics AI Moonshot Program – Advancing AI Strategy and Innovation for Biologics
Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi
Strategies for Discovery of Functional Antibodies to Membrane Protein Targets
Trevor Wilkinson, PhD, Director, Biologics Engineering, AstraZeneca
Analytical Characterization Meets Molecular Modeling: In silico Forced Degradation Studies
Mitja Zidar, PhD, Senior Expert Science and Technology, Novartis
A Library Approach for the de novo High-Throughput Isolation of Humanized VHH Domains with Favorable Developability Properties Following Camelid Immunization
Stefan Zielonka, PhD, Director and Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA